190 related articles for article (PubMed ID: 27721040)
1. Inhibition of glycosylation on a camelid antibody uniquely affects its FcγRI binding activity.
Krahn N; Spearman M; Meier M; Dorion-Thibaudeau J; McDougall M; Patel TR; De Crescenzo G; Durocher Y; Stetefeld J; Butler M
Eur J Pharm Sci; 2017 Jan; 96():428-439. PubMed ID: 27721040
[TBL] [Abstract][Full Text] [Related]
2. Fc-glycosylation influences Fcγ receptor binding and cell-mediated anti-HIV activity of monoclonal antibody 2G12.
Forthal DN; Gach JS; Landucci G; Jez J; Strasser R; Kunert R; Steinkellner H
J Immunol; 2010 Dec; 185(11):6876-82. PubMed ID: 21041724
[TBL] [Abstract][Full Text] [Related]
3. Glycosylation of Fcγ receptors influences their interaction with various IgG1 glycoforms.
Cambay F; Forest-Nault C; Dumoulin L; Seguin A; Henry O; Durocher Y; De Crescenzo G
Mol Immunol; 2020 May; 121():144-158. PubMed ID: 32222585
[TBL] [Abstract][Full Text] [Related]
4. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
Kanda Y; Yamada T; Mori K; Okazaki A; Inoue M; Kitajima-Miyama K; Kuni-Kamochi R; Nakano R; Yano K; Kakita S; Shitara K; Satoh M
Glycobiology; 2007 Jan; 17(1):104-18. PubMed ID: 17012310
[TBL] [Abstract][Full Text] [Related]
5. Identification of Fc Gamma Receptor Glycoforms That Produce Differential Binding Kinetics for Rituximab.
Hayes JM; Frostell A; Karlsson R; Müller S; Martín SM; Pauers M; Reuss F; Cosgrave EF; Anneren C; Davey GP; Rudd PM
Mol Cell Proteomics; 2017 Oct; 16(10):1770-1788. PubMed ID: 28576848
[TBL] [Abstract][Full Text] [Related]
6. In vitro glycoengineering of IgG1 and its effect on Fc receptor binding and ADCC activity.
Thomann M; Schlothauer T; Dashivets T; Malik S; Avenal C; Bulau P; Rüger P; Reusch D
PLoS One; 2015; 10(8):e0134949. PubMed ID: 26266936
[TBL] [Abstract][Full Text] [Related]
7. Generation of site-distinct N-glycan variants for in vitro bioactivity testing.
Brühlmann D; Vuillemin T; Satwekar A; Galano E; Palmese A; D'Angelo A; Manco Z; Souquet J; Broly H; Sauer M; Hemberger J; Jordan M
Biotechnol Bioeng; 2019 May; 116(5):1017-1028. PubMed ID: 30659587
[TBL] [Abstract][Full Text] [Related]
8. Comparison of two glycoengineering strategies to control the fucosylation of a monoclonal antibody.
Mishra N; Spearman M; Donald L; Perreault H; Butler M
J Biotechnol; 2020; 324S():100015. PubMed ID: 34154738
[TBL] [Abstract][Full Text] [Related]
9. Characterizing the effect of multiple Fc glycan attributes on the effector functions and FcγRIIIa receptor binding activity of an IgG1 antibody.
Pace D; Lewis N; Wu T; Gillespie R; Leiske D; Velayudhan J; Rohrbach A; Connell-Crowley L
Biotechnol Prog; 2016 Sep; 32(5):1181-1192. PubMed ID: 27160519
[TBL] [Abstract][Full Text] [Related]
10. Glycan profiling of proteins using lectin binding by Surface Plasmon Resonance.
Wang W; Soriano B; Chen Q
Anal Biochem; 2017 Dec; 538():53-63. PubMed ID: 28947169
[TBL] [Abstract][Full Text] [Related]
11. Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants.
Dashivets T; Thomann M; Rueger P; Knaupp A; Buchner J; Schlothauer T
PLoS One; 2015; 10(12):e0143520. PubMed ID: 26657484
[TBL] [Abstract][Full Text] [Related]
12. Comparison of methods for the analysis of therapeutic immunoglobulin G Fc-glycosylation profiles--part 1: separation-based methods.
Reusch D; Haberger M; Maier B; Maier M; Kloseck R; Zimmermann B; Hook M; Szabo Z; Tep S; Wegstein J; Alt N; Bulau P; Wuhrer M
MAbs; 2015; 7(1):167-79. PubMed ID: 25524468
[TBL] [Abstract][Full Text] [Related]
13. Identification of IgG(1) variants with increased affinity to FcγRIIIa and unaltered affinity to FcγRI and FcRn: comparison of soluble receptor-based and cell-based binding assays.
Lu Y; Vernes JM; Chiang N; Ou Q; Ding J; Adams C; Hong K; Truong BT; Ng D; Shen A; Nakamura G; Gong Q; Presta LG; Beresini M; Kelley B; Lowman H; Wong WL; Meng YG
J Immunol Methods; 2011 Feb; 365(1-2):132-41. PubMed ID: 21185301
[TBL] [Abstract][Full Text] [Related]
14. Characterization of anti-CD20 monoclonal antibody produced by transgenic silkworms (Bombyx mori).
Tada M; Tatematsu K; Ishii-Watabe A; Harazono A; Takakura D; Hashii N; Sezutsu H; Kawasaki N
MAbs; 2015; 7(6):1138-50. PubMed ID: 26261057
[TBL] [Abstract][Full Text] [Related]
15. Strategic feeding of NS0 and CHO cell cultures to control glycan profiles and immunogenic epitopes of monoclonal antibodies.
Villacrés C; Tayi VS; Butler M
J Biotechnol; 2021 Jun; 333():49-62. PubMed ID: 33901620
[TBL] [Abstract][Full Text] [Related]
16. Tuning a MAb glycan profile in cell culture: Supplementing N-acetylglucosamine to favour G0 glycans without compromising productivity and cell growth.
Blondeel EJ; Braasch K; McGill T; Chang D; Engel C; Spearman M; Butler M; Aucoin MG
J Biotechnol; 2015 Nov; 214():105-12. PubMed ID: 26387447
[TBL] [Abstract][Full Text] [Related]
17. Cell type-specific and site directed N-glycosylation pattern of FcγRIIIa.
Zeck A; Pohlentz G; Schlothauer T; Peter-Katalinić J; Regula JT
J Proteome Res; 2011 Jul; 10(7):3031-9. PubMed ID: 21561106
[TBL] [Abstract][Full Text] [Related]
18. Expression of human FcgammaRIIIa as a GPI-linked molecule on CHO cells to enable measurement of human IgG binding.
Armour KL; Smith CS; Clark MR
J Immunol Methods; 2010 Mar; 354(1-2):20-33. PubMed ID: 20138184
[TBL] [Abstract][Full Text] [Related]
19. Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins.
Liu L
J Pharm Sci; 2015 Jun; 104(6):1866-1884. PubMed ID: 25872915
[TBL] [Abstract][Full Text] [Related]
20. Influence of glycan modification on IgG1 biochemical and biophysical properties.
Pawlowski JW; Bajardi-Taccioli A; Houde D; Feschenko M; Carlage T; Kaltashov IA
J Pharm Biomed Anal; 2018 Mar; 151():133-144. PubMed ID: 29324282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
